These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35673254)

  • 1. Migraine Headache in an Employed Population: Demographics, Health Risks, Pharmaceutical Utilization, and Productivity Loss.
    Burton WN; Schultz AB; Shepherd ME; Hines D
    J Occup Environ Med; 2022 Aug; 64(8):679-685. PubMed ID: 35673254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world assessment of concomitant opioid utilization and associated trends in patients with migraine.
    Kangethe A; Polson M; Evangelatos TM; Speicher LC; Tenaglia AT; Staats PS; Liebler EJ; Mwamburi M
    Am J Manag Care; 2020 Feb; 26(1 Suppl):S8-S14. PubMed ID: 32109019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and predictors of opioid use among migraine patients at emergency departments: A retrospective database analysis.
    Shao Q; Rascati KL; Lawson KA; Wilson JP
    Cephalalgia; 2020 Nov; 40(13):1489-1501. PubMed ID: 32781832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-year review of presenteeism data among employees of a large United States health care system: a retrospective prevalence study.
    Allen D; Hines EW; Pazdernik V; Konecny LT; Breitenbach E
    Hum Resour Health; 2018 Nov; 16(1):59. PubMed ID: 30413168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid use and dependence among persons with migraine: results of the AMPP study.
    Buse DC; Pearlman SH; Reed ML; Serrano D; Ng-Mak DS; Lipton RB
    Headache; 2012 Jan; 52(1):18-36. PubMed ID: 22268775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
    Lipton RB; Buse DC; Dodick DW; Schwedt TJ; Singh P; Munjal S; Fanning K; Bostic Bs R; Reed ML
    Headache; 2021 Jan; 61(1):103-116. PubMed ID: 33326608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The acute treatment of episodic and chronic migraine in the USA.
    Bigal ME; Borucho S; Serrano D; Lipton RB
    Cephalalgia; 2009 Aug; 29(8):891-7. PubMed ID: 19222509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey.
    MacGregor EA; Brandes J; Eikermann A
    Headache; 2003 Jan; 43(1):19-26. PubMed ID: 12864754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Virtual Migraine Education Program in an Employed Population.
    Burton WN; Schultz AB; Shepherd ME; McCluskey M; Hines D
    J Occup Environ Med; 2022 Jan; 64(1):52-57. PubMed ID: 34310543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model.
    Gerth WC; Sarma S; Hu XH; Silberstein SD
    J Occup Environ Med; 2004 Jan; 46(1):48-54. PubMed ID: 14724478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing opioid use in a US population with migraine: Results from the CaMEO study.
    Lipton RB; Buse DC; Friedman BW; Feder L; Adams AM; Fanning KM; Reed ML; Schwedt TJ
    Neurology; 2020 Aug; 95(5):e457-e468. PubMed ID: 32527971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the economic burden of migraine on US employers.
    Yucel A; Thach A; Kumar S; Loden C; Bensink M; Goldfarb N
    Am J Manag Care; 2020 Dec; 26(12):e403-e408. PubMed ID: 33315334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia.
    Wong LP; Alias H; Bhoo-Pathy N; Chung I; Chong YC; Kalra S; Shah ZUBS
    J Headache Pain; 2020 Jun; 21(1):68. PubMed ID: 32513174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey.
    Messali A; Sanderson JC; Blumenfeld AM; Goadsby PJ; Buse DC; Varon SF; Stokes M; Lipton RB
    Headache; 2016 Feb; 56(2):306-22. PubMed ID: 26833083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
    Lipton RB; Lee L; Saikali NP; Bell J; Cohen JM
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of lost productivity due to migraine headache: a specific worksite analysis.
    Burton WN; Conti DJ; Chen CY; Schultz AB; Edington DW
    J Occup Environ Med; 2002 Jun; 44(6):523-9. PubMed ID: 12085478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimigraine medication use and associated health care costs in employed patients.
    Wu J; Hughes MD; Hudson MF; Wagner PJ
    J Headache Pain; 2012 Mar; 13(2):121-7. PubMed ID: 22127427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.
    Bigal ME; Serrano D; Reed M; Lipton RB
    Neurology; 2008 Aug; 71(8):559-66. PubMed ID: 18711108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.